BTG3 and systemic lupus erythematosus: They evaluated a wide variety of algorithms using variations of the number of codes in a patient’s record for SLE (1–4 codes), presence of drugs for SLE including anti-malarials, corticosteroids, and disease-modifying antirheumatic drugs (DMARD), and results from ANA tests.